<DOC>
	<DOCNO>NCT01473407</DOCNO>
	<brief_summary>The purpose study demonstrate therapeutic equivalence IV Epoetin Hospira compare IV Epogen ( Amgen ) , base maintenance Hb level study drug dose requirement patient treat anemia associate chronic renal failure hemodialysis .</brief_summary>
	<brief_title>A Phase 3 Study Comparing Effects Intravenous Epoetin Hospira Epoetin Alfa ( Amgen ) Patients With Chronic Renal Failure Requiring Hemodialysis Receiving Epoetin Maintenance Treatment . AiME - Anemia Management With Epoetin</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Patient able provide write informed consent risk benefit study explain prior study related activity 2 . Hemodialysis patient chronic renal failure renal anemia currently stable Epogen ( Amgen ) treatment least 4 week prior randomization , follow apply ( period ) : Epogen ( Amgen ) dose administer intravenously 1 3 time per week 10 % dose change mean least 4 week prior randomization Stable hemoglobin , define meeting following : Mean hemoglobin 4 week prior randomization 9.0 11.0 g/dL No one hemoglobin outside range 9.011.0 g/dL 4 week prior randomization No hemoglobin result ±1 g/dL mean hemoglobin level 4 week period prior randomization 3 . Patients stable , adequate dialysis least 12 week prior randomization , define clinically relevant change dialysis regimen and/or dialyzer 4 . Patients adequate iron store , define ferritin &gt; 100 μg/L TSAT &gt; 20 % , prior randomization 5 . Male female patient age 18 80 year ( inclusive ) 6 . If female , patient must either postmenopausal least 1 year prior randomization , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) , practice least 1 follow method birth control : hormonal contraceptive ( oral , parenteral , transdermal ) least 3 month prior randomization intrauterine device ( IUD ) doublebarrier method ( condom , contraceptive sponge , diaphragm , vaginal ring spermicidal jelly cream ) If hormonal contraceptive use , specific contraceptive must use least 3 month prior randomization . If patient currently use hormonal contraceptive , also use barrier method study least 30 day follow administration patient 's last dose 1 . Maintenance Epoetin dosage &gt; 600 U/kg per week ( 13 time per week ) 2 . Treatment longacting epoetin analogue Aranesp ® within 3 month prior randomization 3 . Any follow within 3 month prior randomization : Myocardial infarction Stroke ( cerebrovascular accident ) /cerebrovascular insult ( minor stroke ) transient ischemic attack/intracerebral bleeding/cerebral infarction Severe/unstable angina Coronary angioplasty , bypass surgery , peripheral artery bypass graft Decompensated congestive heart failure ( New York Heart Association [ NYHA ] class IV ) Pulmonary embolism Deep vein thrombosis thromboembolic event Received live attenuate vaccination ( except flu vaccination ) 4 . Uncontrolled Hypertension within 4 week prior randomization , define 10 % postdialysis blood pressure &gt; 170 mmHg systolic and/or &gt; 110 mmHg diastolic , base blood pressure reading obtain patient 's postdialysis body weight 0.5 kg list dry weight 5 . Known , clinically manifest deficiency folic acid and/or vitamin B12 ( irrespective whether currently treat ) 6 . A patient active , uncontrolled systemic , inflammatory malignant disease ( include demyelinate disease multiple sclerosis ) Investigator 's opinion may significant exclude participation study , include limited microbial , viral , fungal infection mental disease 7 . Contraindication test drug previously treat Epoetin Hospira 8 . Relative absolute iron deficiency prior randomization 9 . Platelet count 100 x 10^9/L 10 . Clinically relevant increase CRP ( &gt; 10 mg/dL ) least 2 week 11 . Significant drug sensitivity significant allergic reaction drug , well know hypersensitivity idiosyncratic reaction epoetin ( excipients , include albumin ) relate drug judgment Investigator exclusionary study participation 12 . History follow : Detectable anti rhEPO antibody Clinically relevant malnutrition Confirmed aluminum intoxication Myelodysplastic syndrome Known bone marrow fibrosis ( osteitis fibrosa cystica ) Known seizure disorder Liver cirrhosis clinical evidence complication ( portal hypertension , splenomegaly , ascites ) 13 . A female patient pregnant , lactate plan pregnancy study 14 . History drug abuse alcohol abuse within 2 year prior randomization determine Investigator 15 . Current participation participation drug investigational research study within 30 day prior randomization 16 . May able comply requirement clinical study , communicate effectively study personnel , consider Investigator , reason , unsuitable candidate study 17 . Donated lose &gt; 475 mL ( i.e. , 1 pint ) blood volume ( include plasmapheresis ) transfusion blood product within 3 month prior randomization 18 . A patient Investigator 's opinion , clinically significant abnormal laboratory evaluation , include liver function take Screening Visit 19 . Positive laboratory test human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( HBsAg )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>